Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Sylvain Ladoire; Jean-Christophe Eymard; Sylvie Zanetta; Grégoire Mignot; Etienne Martin; Isabelle Kermarrec; Eric Mourey; Frédéric Michel; Luc Cormier; François Ghiringhelli

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Sylvain Ladoire ^{1, 2, *} Jean-Christophe Eymard ³ Sylvie Zanetta ¹ Grégoire Mignot ² Etienne Martin ⁴ Isabelle Kermarrec ⁵ Eric Mourey ⁵ Frédéric Michel ⁵ Luc Cormier ⁵ François Ghiringhelli ^{1, 2}

* Auteur correspondant

1 Département d'oncologie médicale [Centre Georges-François Leclerc]

2 LNC - Lipides - Nutrition - Cancer (U866)

3 Service d'oncologie médicale

4 Service de radiothérapie [Centre Georges-François Leclerc]

5 Service d'urologie

Abstract : For this patient population, low dose metronomic cyclophosphamide prednisolone might be a viable alternative. Its convenient oral administration, low cost, and lack of toxicity justify further studies alone, or in combination with other agents in HRPC patients.

Type de document :

Article dans une revue

Domaine :

Sciences du Vivant [q-bio] / Immunologie

Liste complète des métadonnées

https://www.hal.inserm.fr/inserm-00555027
Contributeur : Grégoire Mignot <>
Soumis le : mercredi 12 janvier 2011 - 09:17:19
Dernière modification le : vendredi 8 juin 2018 - 14:50:12

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Identifiants

Collections

Citation

Exporter

Métriques

169

Contact

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Identifiants

Collections

Citation

Exporter

Partager

Métriques

169

Contact